Author

A. Kroh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:Bayesian inference· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:mouse· 1 Research Focus:phylogenetics / evolution· 1 Approach:statistical model· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

A. S. Hatch· 1 shared C. Lopez Iglesias· 1 shared D. Meierhofer· 1 shared F. Aguilera· 1 shared F. Armstrong· 1 shared G. W. Rouse· 1 shared H. Duimel· 1 shared J. R. Thompson· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperEvolutionary Biology

A. S. Hatch

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phylogenomic analyses of echinoid diversification prompt a re-evaluation of their fossil record

N. Mongiardino Koch, J. R. Thompson, A. S. Hatch, M. F. McCowin, F. Armstrong, S. E. Coppard, F. Aguilera, O. Bronstein, A. Kroh, R. Mooi, G. W. Rouse

This study uses phylogenomic data to revise the evolutionary history of echinoids, revealing their origin in the Permian and a Cretaceous origin for sand dollars, conflicting with their fossil record.

bioRxiv · Jul 19, 2021Evolutionary Biology

Enhanced inflammatory response mediated by parenchymal cells associates with resistance towards mTOR inhibition

L. Jiao, R. Eickhoff, S. Jumpertz, J. Roth, M. Erdem, A. Kroh, H. Duimel, C. Lopez Iglesias, M. Schmeding, L. R. Heij, D. Meierhofer, U. P. Neumann, T. Cramer

This study shows that mTOR inhibition in liver epithelial cells enhances inflammation and accelerates liver metastases, suggesting non-malignant cells contribute to resistance against mTOR inhibitors.

bioRxiv · Aug 6, 2020 · PreprintCancer Biology